ClinicalTrials.gg
Not yet recruitingNCT07727486Updated Jul 27, 2026

A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome

A Phase 2 interventional study of ICP-488 Tablets and ICP-488 Placebo in Primary Sjögren's Syndrome, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Not yet recruiting at 22 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in participants with primary Sjögren's syndrome (pSjS).

02

Conditions studied

  • Primary Sjögren's Syndrome
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 70 years inclusive.
  2. The disease duration (from the date of diagnosis) prior to screening shall be at least 24 weeks and no more than 5 years..
  3. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at screening is ≥ 5.
  4. At screening, the stimulated whole salivary flow (SWSF) ≥ 0.05 mL/min OR unstimulated whole salivary flow (UWSF) ≥ 0.01 mL/min.
  5. Positive for anti-Sjögren's-syndrome-related antigen A (anti-SSA/Ro) antibodies at screening.
  6. Stable treatment regimen that can be continued until the end of study treatment (Week 48).
  7. Women of (WOCBP) must agree to use a highly effective method of correctly during the study treatment period and for 1 month (28 days) after the last dose.
  8. Male participants with a WOCBP partner must agree to use protocol-specified contraceptive methods during the study treatment period and for 3 days after the last dose.

Exclusion criteria

Exclusion Criteria

  1. SjS secondary to other systemic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, or systemic sclerosis).
  2. Other autoimmune or inflammatory diseases that could interfere with the assessment of treatment response in SjS.
  3. Presence of any other medical condition associated with SjS symptoms.
  4. Participants with a history of any disease other than pSjS.
  5. Significant abnormalities at screening requiring treatment.
  6. Participants with gastrointestinal diseases or gastrointestinal surgery present within 3 months prior to the screening visit that could affect the absorption of the study drug.
  7. Current or past history of bleeding disorders or diseases related to dysfunction.
  8. Severe infection (bacterial, fungal, or viral) requiring hospitalization within 60 days prior to screening.
  9. Participants with any uncontrolled clinically significant laboratory abnormality that, in the opinion of the investigator, could affect the interpretation of study data or the participant's participation in the study.
  10. Participants considered by the investigator to be unsuitable for participation in this study for any reason.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    ICP-488 Dose A

    Drug: ICP-488 Tablets

  • Experimental
    ICP-488 Dose B

    Drug: ICP-488 Tablets

  • Experimental
    ICP-488 Dose C

    Drug: ICP-488 Tablets

  • Placebo comparator
    ICP-488 Placebo

    Drug: ICP-488 Placebo

Interventions

  • Specified dose on specified days

  • DrugICP-488 Placebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change from baseline in EULAR sjögren's syndrome disease activity index(ESSDAI ) at Week 24

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change from baseline in ESSDAI at each scheduled visit during the 24-week treatment period.

    Time frame: Baseline, Week 24

  2. Percentage (%) of participants achieving a reduction from baseline in ESSDAI of ≥3 points at each scheduled visit during the 24-week treatment period.

    Time frame: Baseline, Week 24

  3. Percentage (%) of participants with ESSDAI <5 at each scheduled visit during the 24-week treatment period.

    Time frame: Baseline, Week 24

  4. Change from baseline in ESSPRI at each scheduled visit during the 24-week treatment period.

    Time frame: Baseline, Week 24

  5. Percentage (%) of participants achieving a reduction from baseline in ESSPRI of ≥1 point or 15% at each scheduled visit during the 24-week treatment period.

    Time frame: Baseline, Week 24

  6. Treatment-emergent adverse events.

    Time frame: Through study completion, an average of 1 year

  7. Incidence of clinically significant abnormalities in laboratory test results, electrocardiograms (ECGs), vital signs, etc., and changes from baseline.

    Time frame: Through study completion, an average of 1 year

  8. Maximum Concentration at Steady State(Cmax,ss)

    Time frame: Through study completion, an average of 1 year

  9. Steady-State Time to Maximum

    Time frame: Through study completion, an average of 1 year

  10. Area under the curve (AUC)

    Time frame: Through study completion, an average of 1 year

07

Study locations

22 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Dec 2028, 28 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 27, 2026
StartEst.
Aug 2026
Primary completionEst.
Dec 2028
CompletionEst.
Mar 2029
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07727486
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Aug 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jul 27, 2026

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-488

Start the discussion